<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03315364</url>
  </required_header>
  <id_info>
    <org_study_id>107CS-5</org_study_id>
    <nct_id>NCT03315364</nct_id>
  </id_info>
  <brief_title>Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy</brief_title>
  <acronym>OPTIMAL</acronym>
  <official_title>A Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel® (Oral Paclitaxel) Compared to Taxol® (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daehwa Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daehwa Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare and evaluate the efficacy and safety of Liporaxel® solution (oral paclitaxel) and
      Taxol® (IV paclitaxel) on recurrent or metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase II clinical trial
Multicenter, Open-label, Single group, Simon's optimal two-stage design
Phase III clinical trial
Multicenter, Open-label, Prospective Randomized Open-label Blinded Endpoint (PROBE)-design trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[Phase II] Overall Response Rate (ORR)</measure>
    <time_frame>Participants will be followed every 6 weeks until progression, an expected average of 9 months.</time_frame>
    <description>Overall Response Rate (ORR) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[Phase III] Progression Free Survival (PFS)</measure>
    <time_frame>From date of randomization, assessed up to 18 months.</time_frame>
    <description>Progression Free Survival (PFS) is defined as the time from date of randomization until the date of first documented progression or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>[Phase II] Progression Free Survival (PFS)</measure>
    <time_frame>From date of randomization, assessed up to 18 months.</time_frame>
    <description>Progression Free Survival (PFS) is defined as the time from date of randomization until the date of first documented progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Phase III] Overall Response Rate (ORR)</measure>
    <time_frame>Participants will be followed every 6 weeks until progression, an expected average of 9 months.</time_frame>
    <description>Overall Response Rate (ORR) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Phase II&amp;III] Overall Survival(OS)</measure>
    <time_frame>Until 6 months after the last participant is enrolled, assessed minimum to 18 months.</time_frame>
    <description>Overall survival(OS) is defined as the time from the date of inclusion to the date of death, regardless of the cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Phase II&amp;III] Time to Treatment Failure(TTF)</measure>
    <time_frame>through study completion, an expected average of 4.5 year.</time_frame>
    <description>TTF is defined as the time from the randomization date to the date of discontinuation of treatment, regardless of the cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Phase II&amp;III] Disease Control Rate(DCR)</measure>
    <time_frame>through study completion, an expected average of 4.5 year.</time_frame>
    <description>DCR is defined as the percentage of subjects who were evaluated for complete response(CR), partial response(PR), and stable disease(SD) as the best response among from randomization to End of treatment(EOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Phase II&amp;III] Quality of life(QoL)</measure>
    <time_frame>C1D1, C2D1, C4D1, C7D1, C10D1 (each cycle is 28 days) and study completion, up to 18 months.</time_frame>
    <description>To evaluate changes versus baseline using the EQ-5D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety]</measure>
    <time_frame>Up to 28 days after last investigational product administraion.</time_frame>
    <description>Number and Description of Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Recurrent or Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Liporaxel® (oral paclitaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28 days (4 weeks) will be set as one cycle of administration and Liporaxel® will be administered for 3 weeks, twice a day, every morning and evening (D1, D8, D15) and will take a week off on 4th week.
Liproaxel® 200mg/m2 will be orally administered twice a day (morning, evening) 1 hour after meal for D1, D8, D15 of every cycle. 10 hour-interval is recommended for between each administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taxol® (IV paclitaxel)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>28 days (4 weeks) will be set as one cycle and for every 3 week administration, 1 week off dose period will be given.
Taxol® 80mg/m2 will be administered via IV and it must be diluted before drip administration. Dilute with 0.9% sodium chloride injection solution to make final concentration of 0.3-1.2 mg/mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral paclitaxel</intervention_name>
    <description>Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent</description>
    <arm_group_label>Liporaxel® (oral paclitaxel)</arm_group_label>
    <other_name>Liporaxel®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel injection</intervention_name>
    <description>Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent</description>
    <arm_group_label>Taxol® (IV paclitaxel)</arm_group_label>
    <other_name>Taxol®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females who are ≥ 19 years of age on the date of signing informed consent.

          2. Subjects with confirmed diagnosis of recurrent or metastatic breast cancer based on
             histopathology examination (tumor characteristics should be confirmed by histologic or
             cytologic evaluation).

               -  Subjects are eligible for the study regardless of hormone receptor status
                  (ER/PR-positive or negative)

               -  ER/PR-positivity is defined as &gt; 1% cells expressing hormone receptors from the
                  metastatic or the primary site based on immunohistochemistry (IHC).

          3. Subjects with diagnosis of HER2-negative breast cancer that was confirmed by IHC or
             ISH assessment of tumor samples (from primary or metastatic site) in any of the
             following cases. (If metastasis is confirmed and it is feasible to obtain the tumor
             sample from the metastatic site, HER2 status assessment must be performed using the
             sample from the metastatic site).

               -  IHC Assessment

                    -  IHC score 0 or 1+

                    -  In case of IHC score 2+, in situ hybridization (ISH) must be performed to
                       confirm HER2 negative breast cancer

               -  ISH Assessment

                    -  Mean HER2 copy number is &lt; 4.0 signals/cell using a single-probe

                    -  Mean HER2 copy number is &lt; 4.0 signals/cell using a dual-probe and the
                       HER2/CEP17 ratio is &lt;2.0

          4. Subjects who have life expectancy of at least 12 weeks.

          5. Subjects who have a performance status of ≤2 on the Eastern Cooperative Oncology Group
             (ECOG) scale.

          6. Subjects who have measurable lesion according to the Response Evaluation Criteria in
             Solid Tumors Version 1.1 (RECIST version 1.1).

          7. Subjects who have adequate organ functions as indicated by the following laboratory
             values:

               -  Absolute neutrophil count (ANC) ≥ 1.500/μL;

               -  Platelet ≥ 100,000 μL;

               -  Hemoglobin ≥ 9.0 g/dL;

               -  Serum creatinine ≤ 1.5 X ULN (but, a subject who has CLcr or eGFR ≥60 mL/min is
                  eligible);

               -  Serum calcium level ≤ 12 mg/dL;

               -  Serum total bilirubin ≤ 1.5 X ULN (but, the increase of bilirubin due to
                  Gilbert's syndrome is excluded);

               -  Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x
                  ULN (or ≤ 5 x ULN for patients with liver metastases).

          8. Subjects who are willing and able to comply with scheduled visits, treatment plans,
             laboratory tests and procedures.

          9. Subjects who have voluntarily agreed to participate by giving written informed consent

        Exclusion Criteria:

          1. Subjects who have history of severe hypersensitive reaction to active ingredient or
             any excipients of Liporaxel® or Taxol®.

          2. Subjects who received prior taxane therapy (If a subject received taxane therapy at
             least 1 year prior to the randomization date and had confirmed relapse, the subject
             will be eligible for the study).

          3. Patients who are currently under first line chemotherapy for recurrent or metastatic
             breast cancer. However patients for following cases are eligible for the study.

               -  Patients whose adjuvant or neoadjuvant treatment for previous breast cancer other
                  than recurrent or metastatic breast cancer was completed more than 1 year ago and
                  treatment related toxicity signs have been disappeared.

               -  In case of ER/PR(+) patients, patients may apply for the study if they finished
                  until second endocrine therapy. (Patients with concomitant use of CDK4/6/
                  inhibitor are also eligible to apply)

          4. Subjects who received radiation therapy within 2 weeks of study randomization (C1D1)
             (If subjects completed local radiation therapy as palliative care to alleviate pain on
             non- target lesions (e.g. sites of bone metastasis) and was recovered from relevant
             acute toxicity (e.g. bone marrow suppression), they are eligible for the study

          5. Subjects who were diagnosed with New York Heart Association (NYHA) Class II congestive
             heart failure or have clinically significant arrhythmia not controlled by medication
             prior to study entry

          6. Subjects who developed cardiovascular disease (unstable angina, myocardial infarction,
             stroke, and transient ischemic attack within 24 weeks prior to study entry and it is
             deemed to be clinically significant by the study investigator

          7. Subjects who have left ventricular ejection fraction (LVEF) below the lower limit of
             normal (LLN) documented by echocardiogram, MUGA scan, or any institutional standard
             procedures within 12 weeks prior to study entry (When the normal value is not
             established, LVEF of 50 % is considered to be normal).

          8. Subjects with uncontrolled hypertension despite medication treatment at the time of
             randomization. ( patients with SBP &gt; 140 mmHg or DBP &gt; 90 mmHg despite using
             medication )

          9. Subjects with known active hepatitis B or C, or hepatobiliary disease (however
             patients may participate on following cases)

               -  Subjects with Gilbert's Syndrome, asymptomatic gallstones, hepatocellular
                  carcinoma, or stable chronic liver disease at the discretion of the investigator
                  are eligible for the study.

               -  Subjects who are hepatitis B or C carriers may be eligible if they are on
                  antiviral therapy prior to study entry (in case of HCV ab positive, if HCV RNA
                  titer is negative then the patient is not considered as a hepatitis C carrier).

         10. Subjects with known history of Human immunodeficiency virus (HIV)

         11. Subjects with neuropathy grade ≥2 based on CTCAE v4.03 at the time of study entry

         12. Subjects with uncontrolled serious medical or mental illness including a social status
             which may affect treatment compliance at the investigator's discretion.

         13. Subjects diagnosed with other malignant primary tumor with the exception of
             followings:

               -  Malignancy fully treated at least 5 years previously or disease-free condition

               -  At least 1 year after the complete excision of basal /squamous cell carcinoma, a
                  radical mastectomy of papillary thyroid carcinoma or the complete treatment of
                  cervical intraepithelial neoplasia.

         14. Subjects with metastases to the central nervous system at the time of screening (If
             subjects have a symptom, metastases to the central nervous system will be confirmed by
             neuroimaging at investigator's discretion).

         15. Subjects who are expected to receive bisphosphonate at the time of study entry under
             the investigator's discretion or who are expected to be given during the course of the
             trial, such as prophylactic use in the absence of any bone disease (However, subjects
             who are receiving bisphosphonate prior to administration of study drug for the
             treatment of bone metastases or osteoporosis are eligible for the study and the
             concomitant use of bisphosphonates is allowed during the study period.

         16. Subjects who have a problem with oral administration at the investigator's discretion

               -  Subjects who had innate or acquired serious or uncontrolled gastrointestinal
                  disease

               -  Subjects with bowel obstruction or inflammatory bowel disease (Crohn's disease,
                  chronic inflammation) that could affect the administration and absorption of oral
                  medication at the investigator's discretion

         17. Pregnant or breastfeeding women

         18. Women with childbearing potential who are not willing to use appropriate method of
             contraception during the duration of the study and for at least 12 weeks following the
             last dose of study drug

         19. Subjects who have received any investigational drugs or devices within 4 weeks from
             screening.

         20. Subjects who are in a state that is deemed inappropriate to participate in the
             clinical trial by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keun Seok Lee, M.D., Ph.D</last_name>
      <phone>031-920-1623</phone>
      <email>kslee@ncc.re.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seok Yun Kang, M.D.,Ph.D</last_name>
      <phone>031-219-4911</phone>
      <email>kagnsy01@ajou.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyung-hwa Park, M.D., Ph.D</last_name>
      <phone>02-920-6841</phone>
      <email>khpark@korea.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tae-yong Kim, M.D., Ph.D</last_name>
      <phone>02-2072-3116</phone>
      <email>ktyongmd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joo Hyuk Sohn, M.D.,Ph.D</last_name>
      <phone>02-2228-8135</phone>
      <email>oncosohn@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sung-bae Kim, M.D., Ph.D</last_name>
      <phone>02-3010-3217</phone>
      <email>sbkim3@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Young-Hyuck Im, M.D., Ph.D</last_name>
      <phone>02-3410-3445</phone>
      <email>yh00.im@samsung.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae Hong Seo, M.D., Ph.D</last_name>
      <phone>02-2626-3059</phone>
      <email>cancer@korea.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent breast cancer</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>MBC</keyword>
  <keyword>Firstline chemotherapy</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Liporaxel</keyword>
  <keyword>Taxol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

